XML 48 R13.htm IDEA: XBRL DOCUMENT
v3.25.1

Segment Reporting | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting [Abstract] |
Segment Reporting |
3 | SEGMENT REPORTING
For the years ended December 31, 2022, 2023 and 2024, the Group had three operating segments, including central laboratory business, in-hospital business and pharma research and development services. The operating segments also represented the reporting segments. The CODM considers year-over-year fluctuations and budget-to-actual variances of the operating segments based on the measures of revenues, cost of revenue and gross profit by central laboratory business, in-hospital business and pharma research and development services when assessing performance and deciding how to allocate resources. Other than the information provided below, the CODM does not use any other measures by segment. There are no inter-segment revenue transactions and, therefore, revenues are only generated from external customers. The accounting policies of the segments are the same as those used by the Group. The Group prepared the financial results of the operating segments on a basis that is consistent with the manner in which management internally disaggregates financial information to assist in making internal operating decisions. The reconciliation of gross profit of reportable segments to consolidated loss before income tax was consistent with the consolidated statements of comprehensive loss. Summarized information by segments for the years ended December 31, 2022, 2023 and 2024 is as follows:
|  | For the year ended December 31, 2022 |
|  | Central laboratory business |  |  | In-hospital business |  |  | Pharma research and development services |  |  | Total |
|  | RMB |  |  | RMB |  |  | RMB |  |  | RMB |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues from services |  |  | 314,770 |  |  |  | 3,606 |  |  |  | 73,172 |  |  |  | 391,548 |
Revenues from sales of products |  |  | — |  |  |  | 171,690 |  |  |  | — |  |  |  | 171,690 |
Total revenues |  |  | 314,770 |  |  |  | 175,296 |  |  |  | 73,172 |  |  |  | 563,238 |
Cost of revenues: |  |  | (82,123 | ) |  |  | (63,296 | ) |  |  | (37,780 | ) |  |  | (183,199 | )
Gross profit |  |  | 232,647 |  |  |  | 112,000 |  |  |  | 35,392 |  |  |  | 380,039 |
|  | For the year ended December 31, 2023 |
|  | Central laboratory business |  |  | In-hospital business |  |  | Pharma research and development services |  |  | Total |
|  | RMB |  |  | RMB |  |  | RMB |  |  | RMB |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues from services |  |  | 232,812 |  |  |  | (3,704 | ) |  |  | 115,922 |  |  |  | 345,030 |
Revenues from sales of products |  |  | — |  |  |  | 192,405 |  |  |  | — |  |  |  | 192,405 |
Total revenues |  |  | 232,812 |  |  |  | 188,701 |  |  |  | 115,922 |  |  |  | 537,435 |
Cost of revenues: |  |  | (49,473 | ) |  |  | (72,570 | ) |  |  | (52,165 | ) |  |  | (174,208 | )
Gross profit |  |  | 183,339 |  |  |  | 116,131 |  |  |  | 63,757 |  |  |  | 363,227 |
|  | For the year ended December 31, 2024 |
|  | Central laboratory business |  |  | In-hospital business |  |  | Pharma research and development services |  |  | Total |
|  | RMB |  |  | US$ |  |  | RMB |  |  | US$ |  |  | RMB |  |  | US$ |  |  | RMB |  |  | US$ |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues from services |  |  | 175,649 |  |  |  | 24,064 |  |  |  | (592 | ) |  |  | (81 | ) |  |  | 115,681 |  |  |  | 15,848 |  |  |  | 290,738 |  |  |  | 39,831 |
Revenue from sales of products |  |  | — |  |  |  | — |  |  |  | 225,084 |  |  |  | 30,836 |  |  |  | — |  |  |  | — |  |  |  | 225,084 |  |  |  | 30,836 |
Total revenues |  |  | 175,649 |  |  |  | 24,064 |  |  |  | 224,492 |  |  |  | 30,755 |  |  |  | 115,681 |  |  |  | 15,848 |  |  |  | 515,822 |  |  |  | 70,667 |
Cost of revenues: |  |  | (33,808 | ) |  |  | (4,632 | ) |  |  | (65,099 | ) |  |  | (8,919 | ) |  |  | (54,515 | ) |  |  | (7,469 | ) |  |  | (153,422 | ) |  |  | (21,020 | )
Gross profit |  |  | 141,841 |  |  |  | 19,432 |  |  |  | 159,393 |  |  |  | 21,836 |  |  |  | 61,166 |  |  |  | 8,379 |  |  |  | 362,400 |  |  |  | 49,647 |
Geographic information The analysis of the total long-lived assets excluding equity method investment, convertible note receivable and intangible assets by country was as follows:
|  | As of December 31, |
|  | 2023 |  |  | 2024 |
|  | RMB |  |  | RMB |  |  | US$ |
PRC |  |  | 127,866 |  |  |  | 102,154 |  |  |  | 13,996 |
United States |  |  | 21,418 |  |  |  | 6,112 |  |  |  | 837 |
|  |  | 149,284 |  |  |  | 108,266 |  |  |  | 14,833 |
Total revenues by geographic area are presented as follows:
|  | For the year ended December 31, |
|  | 2022 |  |  | 2023 |  |  | 2024 |
|  | RMB |  |  | RMB |  |  | RMB |  |  | US$ |
PRC |  |  | 553,304 |  |  |  | 534,928 |  |  |  | 510,241 |  |  |  | 69,902 |
United States |  |  | 9,934 |  |  |  | 2,507 |  |  |  | 5,581 |  |  |  | 765 |
|  |  | 563,238 |  |  |  | 537,435 |  |  |  | 515,822 |  |  |  | 70,667 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration